EA201591665A1 - Оральные составы деферазирокса - Google Patents

Оральные составы деферазирокса

Info

Publication number
EA201591665A1
EA201591665A1 EA201591665A EA201591665A EA201591665A1 EA 201591665 A1 EA201591665 A1 EA 201591665A1 EA 201591665 A EA201591665 A EA 201591665A EA 201591665 A EA201591665 A EA 201591665A EA 201591665 A1 EA201591665 A1 EA 201591665A1
Authority
EA
Eurasian Patent Office
Prior art keywords
deferasyrox
oral structures
neutral
disclosed
oral
Prior art date
Application number
EA201591665A
Other languages
English (en)
Other versions
EA031719B1 (ru
Inventor
Индраджит Гхош
Цзя-Ай Чжан
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201591665(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201591665A1 publication Critical patent/EA201591665A1/ru
Publication of EA031719B1 publication Critical patent/EA031719B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Раскрыты орально вводимые составы деферазирокса, имеющие сниженное высвобождение при условиях желудка и быстрое высвобождение при почти нейтральном рН или нейтральном рН.
EA201591665A 2013-03-08 2014-03-06 Оральные составы деферазирокса EA031719B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361774893P 2013-03-08 2013-03-08
US201361824435P 2013-05-17 2013-05-17
PCT/IB2014/059494 WO2014136079A1 (en) 2013-03-08 2014-03-06 Oral formulations of deferasirox

Publications (2)

Publication Number Publication Date
EA201591665A1 true EA201591665A1 (ru) 2015-12-30
EA031719B1 EA031719B1 (ru) 2019-02-28

Family

ID=50288212

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591665A EA031719B1 (ru) 2013-03-08 2014-03-06 Оральные составы деферазирокса

Country Status (42)

Country Link
US (4) US9283209B2 (ru)
EP (2) EP3124018B2 (ru)
JP (3) JP6434429B2 (ru)
KR (2) KR101925671B1 (ru)
CN (1) CN105025886B (ru)
AP (1) AP2015008668A0 (ru)
AU (2) AU2014224198B2 (ru)
BR (1) BR112015021254A2 (ru)
CA (1) CA2890465A1 (ru)
CL (1) CL2015002495A1 (ru)
CR (1) CR20150467A (ru)
CU (1) CU24348B1 (ru)
CY (2) CY1120021T1 (ru)
DK (2) DK2964202T3 (ru)
DO (1) DOP2015000220A (ru)
EA (1) EA031719B1 (ru)
EC (1) ECSP15042897A (ru)
ES (2) ES2708955T5 (ru)
HK (1) HK1212242A1 (ru)
HR (2) HRP20180387T1 (ru)
HU (2) HUE036921T2 (ru)
IL (1) IL240797B (ru)
JO (1) JO3570B1 (ru)
LT (2) LT3124018T (ru)
ME (1) ME03297B (ru)
MX (1) MX361055B (ru)
MY (1) MY170303A (ru)
NI (1) NI201500126A (ru)
NZ (1) NZ711179A (ru)
PE (1) PE20151600A1 (ru)
PH (1) PH12015501981A1 (ru)
PL (2) PL3124018T3 (ru)
PT (2) PT2964202T (ru)
RS (2) RS58317B1 (ru)
SA (1) SA515360425B1 (ru)
SG (2) SG11201506491RA (ru)
SI (2) SI3124018T1 (ru)
TN (1) TN2015000393A1 (ru)
TW (2) TWI625136B (ru)
UY (1) UY35367A (ru)
WO (1) WO2014136079A1 (ru)
ZA (1) ZA201506060B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI625136B (zh) 2013-03-08 2018-06-01 諾華公司 祛鐵斯若（ｄｅｆｅｒａｓｉｒｏｘ）之口服配方
US9866684B2 (en) * 2015-02-16 2018-01-09 Microsoft Technology Licensing, Llc Process for real-time data exchange between users on a phone call
WO2016167729A1 (en) * 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
WO2016205658A1 (en) 2015-06-17 2016-12-22 Dispersol Technologies, Llc Improved formulations of deferasirox and methods of making the same
EP3429562A1 (en) 2016-03-17 2019-01-23 Lupin Limited Compositions of deferasirox
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CA3029543C (en) * 2016-07-05 2021-11-23 Jubilant Generics Limited Immediate release pharmaceutical composition of iron chelating agents
WO2018059922A1 (en) 2016-09-30 2018-04-05 Synthon B.V. Pharmaceutical composition comprising deferasirox
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
TR201707764A2 (tr) * 2017-05-29 2018-12-21 Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasiroksun bölünebilir tablet formları.
WO2019108156A1 (en) * 2017-11-28 2019-06-06 Biofarma Ilac Sanayi Ve Ticaret A.S. A scored tablet formulation comprising deferasirox in a film tablet form
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
WO2022186809A1 (en) * 2021-03-05 2022-09-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi The film coated tablet comprising deferasirox
CN115154428B (zh) * 2022-09-06 2023-01-10 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129541A (en) * 1996-06-25 2007-04-30 Novartis Ag Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
KR20070022243A (ko) * 2004-04-08 2007-02-26 노파르티스 아게 데페라시록스 분산성 정제
GB0408078D0 (en) 2004-04-08 2004-05-12 Novartis Ag Organic compounds
CN101291655A (zh) * 2005-10-19 2008-10-22 诺瓦提斯公司 包含地拉罗司(deferasirox)的分散片
WO2009067557A1 (en) † 2007-11-19 2009-05-28 Teva Pharmaceutical Industries Ltd. Deferasirox pharmaceutical compositions
WO2009106824A2 (en) 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
EP2291360A2 (en) * 2008-04-21 2011-03-09 Actavis Group PTC ehf. Solid state forms of deferasirox salts and process for the preparation thereof
WO2010035282A1 (en) 2008-09-24 2010-04-01 Matrix Laboratories Limited Pharmaceutical compositions comprising deferasirox
WO2010143006A1 (en) * 2009-06-10 2010-12-16 Carlo Ghisalberti Orally bioavailable iron chelators in the treatment of an inflammatory bowel disease
EA201390079A1 (ru) * 2010-07-08 2013-09-30 Рациофарм Гмбх Пероральная лекарственная форма деферазирокса
KR20140011300A (ko) * 2010-10-01 2014-01-28 시플라 리미티드 데페라시록스를 포함하는 약학 조성물
TWI625136B (zh) 2013-03-08 2018-06-01 諾華公司 祛鐵斯若（ｄｅｆｅｒａｓｉｒｏｘ）之口服配方
EP3429562A1 (en) 2016-03-17 2019-01-23 Lupin Limited Compositions of deferasirox

Also Published As

Publication number Publication date
CN105025886A (zh) 2015-11-04
JO3570B1 (ar) 2020-07-05
PH12015501981B1 (en) 2016-01-11
TW201838623A (zh) 2018-11-01
DK3124018T3 (en) 2018-03-26
EP3124018B1 (en) 2017-12-20
US9283209B2 (en) 2016-03-15
CY1120021T1 (el) 2018-12-12
CN105025886B (zh) 2019-01-15
PH12015501981A1 (en) 2016-01-11
TWI686215B (zh) 2020-03-01
US20160220493A1 (en) 2016-08-04
HUE041224T2 (hu) 2019-05-28
TWI625136B (zh) 2018-06-01
EA031719B1 (ru) 2019-02-28
DOP2015000220A (es) 2015-11-30
WO2014136079A1 (en) 2014-09-12
KR20170045391A (ko) 2017-04-26
ES2708955T5 (es) 2023-11-10
JP2016510068A (ja) 2016-04-04
ECSP15042897A (es) 2019-03-29
JP2018162255A (ja) 2018-10-18
LT3124018T (lt) 2018-03-12
IL240797B (en) 2022-01-01
JP6434429B2 (ja) 2018-12-05
US20150017241A1 (en) 2015-01-15
KR101925671B1 (ko) 2019-02-27
AU2014224198A1 (en) 2015-09-10
HUE036921T2 (hu) 2018-08-28
NZ711179A (en) 2018-07-27
SG10201807204YA (en) 2018-09-27
NI201500126A (es) 2015-11-18
ES2663135T3 (es) 2018-04-11
RS58317B1 (sr) 2019-03-29
CU24348B1 (es) 2018-05-08
US20180221285A1 (en) 2018-08-09
SA515360425B1 (ar) 2018-01-21
JP2020180123A (ja) 2020-11-05
AU2017203897B2 (en) 2019-02-14
MX361055B (es) 2018-11-26
EP2964202A1 (en) 2016-01-13
EP2964202B2 (en) 2023-05-31
TW201442742A (zh) 2014-11-16
BR112015021254A2 (pt) 2017-07-18
EP2964202B1 (en) 2018-10-31
RS56890B1 (sr) 2018-04-30
SG11201506491RA (en) 2015-09-29
CU20150110A7 (es) 2016-04-25
KR20150126900A (ko) 2015-11-13
EP3124018B2 (en) 2024-04-24
AP2015008668A0 (en) 2015-08-31
EP3124018A1 (en) 2017-02-01
ES2708955T3 (es) 2019-04-12
LT2964202T (lt) 2019-02-11
PT2964202T (pt) 2019-02-06
JP6739470B2 (ja) 2020-08-12
HRP20190173T1 (hr) 2019-03-22
CL2015002495A1 (es) 2016-03-04
HK1212242A1 (en) 2016-06-10
US20170290811A1 (en) 2017-10-12
CA2890465A1 (en) 2014-09-12
MY170303A (en) 2019-07-17
PL2964202T3 (pl) 2019-04-30
PT3124018T (pt) 2018-03-22
UY35367A (es) 2014-10-31
ZA201506060B (en) 2016-12-21
IL240797A0 (en) 2015-10-29
ME03297B (me) 2019-07-20
PE20151600A1 (es) 2015-11-26
CR20150467A (es) 2015-10-27
DK2964202T3 (en) 2019-02-25
SI2964202T1 (sl) 2019-02-28
HRP20180387T1 (hr) 2018-04-20
TN2015000393A1 (en) 2017-01-03
PL3124018T3 (pl) 2018-05-30
AU2014224198B2 (en) 2017-06-15
MX2015011962A (es) 2016-07-07
SI3124018T1 (en) 2018-04-30
CY1121315T1 (el) 2020-05-29
AU2017203897A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
EA201591665A1 (ru) Оральные составы деферазирокса
CL2016002455A1 (es) Anticuerpos multiespecíficos.
ECSP18007905A (es) Anticuerpos monoclonales contra bcma
EA201990615A1 (ru) Пирролобензодиазепиновые конъюгаты
MD3370770T2 (ro) Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
UY34763A (es) Inhibidores de la agregación plaquetaria
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
UY34817A (es) Tienopirimidinas
DK2986726T3 (da) Hidtil ukendte bacillusstammesammensætninger
EA201591615A1 (ru) Замещенные ксантины и способы их применения
DK3244878T3 (da) Faste orale sammensætningsformer
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
EA201290642A1 (ru) Соединения и способы
FR3012409B1 (fr) Chaine d'ancrage
DK3331498T3 (da) Nasalsammensætning
DK3411008T3 (da) Sammensætninger omfattende aktive solbeskyttelsesmidler med polyhydroxyfulleren
DK3397734T3 (da) Brændstofsammensætning
DK3041579T3 (da) Orale antiparasitære sammensætninger
EA201591709A1 (ru) 5-бром-индирубины

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ